Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.3K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

639
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum IgG, definite anti-dsDNA positivity, and advanced HBV-related liver disease: a laboratory-based retrospective study.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

Advancing proteomic discovery through optimized multi-stage scoring and deep learning-enhanced open search.

Bioinformatics (Oxford, England)·2026
Same author

Molecular characterization and correlation with β-lactam resistance of penicillin-binding protein2x, 2b, and 1a of <i>Streptococcus pneumoniae</i> in clinical pneumococcal isolates.

Microbiology spectrum·2026
Same author

Magnetic Resonance Spectroscopy Deep Learning with Magnetic Resonance Background Generator Enables In Vivo Metabolite Quantification of Hepatic Encephalopathy.

IEEE transactions on bio-medical engineering·2026
Same author

PolyMamba-Net: a lightweight and boundary-aware network for real-time polyp segmentation in colonoscopy.

Frontiers in medicine·2026
Same author

Triglyceride-glucose index and systemic immune-inflammation index are associated with left ventricular hypertrophy in type 2 diabetes mellitus patients.

BMC endocrine disorders·2026

Related Experiment Video

Updated: Aug 25, 2025

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
11:00

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection

Published on: June 23, 2023

1.2K

RIPK3 modulates sarcoma through immune checkpoint HAVCR2.

Chen Qian1, Deluo Wu1, Jianwei Du1

  • 1Department of Orthopedics, Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu 225000, P.R. China.

Oncology Letters
|October 14, 2022
PubMed
Summary
This summary is machine-generated.

Receptor interacting serine/threonine kinase 3 (RIPK3) expression in sarcoma correlates with better survival and immune response. Increased RIPK3 may improve outcomes by regulating immune checkpoints like HAVCR2, suggesting RIPK3 as a potential therapeutic target.

Keywords:
HAVCR2RIPK3sarcoma

More Related Videos

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model
09:03

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model

Published on: October 16, 2017

8.8K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.3K

Related Experiment Videos

Last Updated: Aug 25, 2025

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection
11:00

Real-Time Quantitative Measurement of Tumor Cell Migration and Invasion Following Synthetic mRNA Transfection

Published on: June 23, 2023

1.2K
Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model
09:03

Identification and Characterization of Metastatic Factors by Gene Transfer into the Novel RIP-Tag; RIP-tva Murine Model

Published on: October 16, 2017

8.8K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Sarcomas are complex cancers with unclear molecular drivers.
  • Receptor interacting serine/threonine kinase 3 (RIPK3) is linked to immune diseases and aggressive tumors.

Purpose of the Study:

  • To investigate the role of RIPK3 in sarcoma.
  • To analyze RIPK3's impact on gene expression, pathways, immune checkpoints, and cell infiltration in sarcoma.

Main Methods:

  • Utilized The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research To Generate Effective Treatments (TARGET) databases for transcriptome sequencing data mining.
  • Performed gene expression analysis, pathway enrichment, immune cell infiltration analysis, and reverse transcription-quantitative PCR (RT-qPCR).

Main Results:

  • Identified 603 upregulated and 260 downregulated genes in higher RIPK3 expression groups.
  • Found RIPK3 expression associated with improved survival, hepatitis A virus cellular receptor 2 (HAVCR2), and better response to immune blockade therapy.
  • RIPK3 positively correlated with macrophage and monocyte infiltration and modulated HAVCR2 expression.

Conclusions:

  • RIPK3 plays a significant role in sarcoma prognosis and immune modulation.
  • Increased RIPK3 expression may enhance survival via regulation of immune checkpoint HAVCR2.
  • RIPK3 represents a potential therapeutic target for sarcoma treatment.